High throughput screening (HTS) is an established means to identify starting points in the drug discovery process. As a significant investment is necessary to undertake high throughput screening efficiently, screening is increasingly being outsourced by researchers in the not-for-profit, biotechnology and pharmaceutical sectors. Access to high throughput screening expertise and technology without the need to implement in-house compound libraries and the required screening and data handling platforms has proven effective at reducing operational and infrastructure costs.
The webinar will provide an overview of the screening process from assay development through to the final data package by exploring examples of successful high throughput screening programs we have conducted in our lab. During the course of the discussion, the speakers will describe various assay options in common use and whether highly miniaturised and/or automated platforms are applicable in all situations. Drilling into the details common to these successful programs, they will reveal insights on points to consider and questions to ask when considering different labs to work with on your project.
- Explain the screening process from assay development to final data package
- Describe assay options and which platforms are applicable for different types of projects
- Provide insight on key points to consider when outsourcing
David Cronk, CBiol, MSB, Director, Hit Discovery, Charles River Laboratories, Early Discovery, Chesterford Research Park, Saffron Walden, UK
With over 25 years of drug discovery experience, David spent approximately 15 years within the GlaxoSmithKline organisation providing assay development expertise and assay support for a number of disease related projects, largely focused on cell based assays for GPCR and ion channel targets, ultimately becoming responsible for the ion channel high throughput screening team at the GSK Stevenage facility. From GSK, David joined Ionix Pharmaceuticals, a biotech company engaged in analgesia drug discovery, where he headed the molecular pharmacology team conducting screening and profiling activities for the company’s portfolio of targets.
David is currently the Director of Hit Discovery at Charles River responsible for the all assay development, high throughput screening and compound management activities. He takes a very “hands on” approach to project management, regularly reviews data and provides insight and guidance on assay troubleshooting, data interpretation and hit calling.Message Presenter
Victoria Wong, PhD, Senior Principal Scientist, Pfizer
Victoria started her HTS career in the Lead Discovery and Profiling group at Bristol-Myers Squib in 2000. In 2006, she joined Pfizer as an HTS lab head and then in 2009 Victoria took a new position in External Research Solutions in Pfizer, managing outsourcing research projects for Pfizer.Message Presenter
Who Should Attend?
VPs/Directors/Managers/Senior Scientists & Research Scientists working within:
- Drug Discovery
- Translational Science
- High Throughput Screening
- Hit Finding
- Biochemical and Cell Based Assay Development
- Screening Libraries
From Pharmaceutical and Biotechnology companies
As your scientific partner and preclinical CRO provider, Charles River provides innovation, flexibility, and efficiency in IND-enabling studies from early discovery research and in vivo pharmacology models through safety assessment. Our unique combination of interdisciplinary, multi-disciplinary drug discovery expertise and unparalleled scope of capabilities in targets, platforms, and therapeutic areas allow us to deliver depth and breadth in science with insight and data you can trust to progress your drug discovery programs at any point along the way, from your very first research question about a molecule to a drug candidates’ first trial in man.